Paper - WANFANG MED ONLINE

You Position: Home > Paper

Quantitative prediction of in vivo drug-drug interactions based on in vitro inhibition or/and induction data for CYP3A4

( views:25, downloads:0 )

Author:: No author available

Journal Title:: ACTA PHARMACEUTICA SINICA

Issue:: 8

DOI:: No doi available

Key Word:: CYP3A4;药物-药物相互作用;预测模型;诱导;抑制

Abstract：抑制和诱导CYP3A4所引起的药动学药物相互作用是临床药物相互作用的常见机制之一,在新药研究以及临床应用中已引起广泛关注.在新药研发早期定量预测药物相互作用可缩短新药开发的时间和成本,并为后期的临床研究提供参考依据.本文综述了近年应用体外CYP3A4代谢数据构建数学模型定量预测体内药物相互作用的研究进展.

Reference

[1]Kent UM,Bumpus NN,Hollenberg PF.Mechanism-based inactivation of human cytochromes p450s: experimental characterization, reactive intermediates, and clinical implications.[J].2008,21(1).
[2]Mayhew BS,Hall SD,Jones DR.An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation.[J].2000,28(9).
[3]Rostami Hodjegan A,Bloomer JC,Tucker GT,etc.A critical evaluation of the experimental design of studies of mechanism based enzyme inhibition, with implications for in vitro-in vivo extrapolation.[J].2006,7(3).
[4]Zhang X,Quinney SK,Gorski JC.Semiphysiologically based pharmacokinetic models for the inhibition of midazolam clearance by diltiazem and its major metabolite.[J].2009,37(8).
[5]Chen Y,Pan,Xu L.Prediction of human drug-drug interactions from time-dependent inactivation of CYP3A4 in primary hepatocytes using a population-based simulator.[J].2009,37(12).
[6]Einolf HJ.Comparison of different approaches to predict metabolic drug-drug interactions.[J].2007,37(10).
[7]Nicola J, Hewitt,María José Gómez, Lechón,J Brian, Houston,etc.Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies.[J].2007,39(1).
[8]Kalgutkar AS,Maurer TS,Obach RS.Mechanism-based inactivation of cytochrome p450 enzymes: chemical mechanisms, structure-activity relationships and relationship to clinical drug-drug interactions and idiosyncratic adverse drug reactions.[J].2007,8(5).
[9]Y, B?ttiger,G, Tybring,E, G?tharson,etc.Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin.[J].1997,62.
[10]Lu C,Berg C,Balani SK,etc.Prediction of pharmacokinetic drug-drug interactions using human hepatocyte suspension in plasma and cytochrome P450 phenotypic data. II. In vitro-in vivo correlation with ketoconazole.[J].2008,36(7).
[11]Robert L Walsky,J.Brian Houston,Emily A.Gaman,etc.The Utility of in Vitro Cytochrome P450 Inhibition Data in the Prediction of Drug-Drug Interactions[J].2006,316(1).
[12]Obach RS,Walsky RL,Venkatakrishnan K.Mechanism-based inactivation of human cytochrome p450 enzymes and the prediction of drug-drug interactions.[J].2007,35(2).
[13]Pan Y,Hayashi M,Xu Y,etc.Modeling, prediction, and in vitro in vivo correlation of CYP3A4 induction.[J].2008,36(11).
[14]Cardenas E,Fahmi OA,Boldt S,etc.A combined model for predicting CYP3A4 clinical net drug-drug interaction based on CYP3A4 inhibition, inactivation, and induction determined in vitro.[J].2008,36(8).
[15]Hamman MA,O'Mara EM Jr,Jones DR,etc.The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin.[J].1998,64(2).
[16]J T, Moore,S A, Kliewer.Use of the nuclear receptor PXR to predict drug interactions.[J].2000,153(1-3).
[17]Venkatakrishnan K,Von-Moltke LL,Greenblatt DJ.Human drug metabolism and the cytochromes P450: application and relevance of in vitro models.[J].2001,41(11).
[18]Stephen, Fowler,Hongjian, Zhang.In vitro evaluation of reversible and irreversible cytochrome P450 inhibition: current status on methodologies and their utility for predicting drug-drug interactions.[J].2008,10(2).
[19]Rodrigues AD.Integrated cytochrome P450 reaction phenotyping: attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes.[J].1999,57(5).
[20]L C, Floren,I, Bekersky,L Z, Benet,etc.Tacrolimus oral bioavailability doubles with coadministration of ketoconazole.[J].1997,62.
[21]Ribadeneira MD,Zech K,Mudra DR,etc.Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes.[J].2003,31(4).
[22]Hyland R,Gibbs JP,Youdim K.Minimizing polymorphic metabolism in drug discovery: evaluation of the utility of in vitro methods for predicting pharmacokinetic consequences associated with CYP2D6 metabolism.[J].2006,34(9).
[23].Potential role of intestinal first-pass metabolism in the prediction of drug-drug interactions.[J].2008,4(7).
[24]Brown HS,Ito K,Galetin A,etc.Prediction of in vivo drug-drug interactions from in vitro data: impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant.[J].2005,60(5).
[25]Lu C,Berg C,Balani SK,etc.Prediction of pharmacokinetic drug-drug interactions using human hepatocyte suspension in plasma and cytochrome P450 phenotypic data. III. In vitro-in vivo correlation with fluconazole.[J].2008,36(7).
[26]Grime KH,Bird J,Ferguson D,etc.Mechanism-based inhibition of cytochrome P450 enzymes: an evaluation of early decision making in vitro approaches and drug-drug interaction prediction methods.[J].2009,36(2/3).
[27]Anthony M,Zhu Z,Rodrigues AD,etc.Evaluation of 170 Xenobiotics as Transactivators of Human Pregnane X Receptor (hPXR) and Correlation to Known CYP3A4 Drug Interactions.[J].2006,7(4).
[28]Karen Rowland Yeo,Amin Rostami-Hodjegan,Jiansong Yang,etc.Prediction of Intestinal First-Pass Drug Metabolism[J].2007,8(7).
[29]Fahmi OA,Boldt S,Kish M,etc.Prediction of drug-drug interactions from in vitro induction data: application of the relative induction score approach using cryopreserved human hepatocytes.[J].2008,36(9).
[30]Houston JB,Hallifax D.Saturable uptake of lipophilic amine drugs into isolated hepatocytes: mechanisms and consequences for quantitative clearance prediction.[J].2007,35(8).
[31]Zhao P.The use of hepatocytes in evaluating time-dependent inactivation of P450 in vivo.[J].2008,4(2).
[32]Ueno M,Ohno Y,Suzuki H,etc.General Framework for the Prediction of Oral Drug Interactions Caused by CYP3A4 Induction from In Vivo Information.[J].2008,47(10).
[33]Greenblatt DJ,Velez RL,Tsunoda SM,etc.Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole.[J].1999,66(5).
[34]J. Brian Houston,Laura K. Hinton,Howard Burt,etc.Maximal Inhibition of Intestinal First-Pass Metabolism as a Pragmatic Indicator of Intestinal Contribution to the Drug-Drug Interactions for CYP3A4 Cleared Drugs[J].2007,8(7).
[35]Plowchalk D,Fahmi OA,Hurst S.Comparison of different algorithms for predicting clinical drug-drug interactions, based on the use of CYP3A4 in vitro data: predictions of compounds as precipitants of interaction.[J].2009,37(8).
[36]Goodwin B,Hodgson E,Liddle C.The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module.[J].1999,56(6).
[37]F Peter, Guengerich.Cytochromes P450, drugs, and diseases.[J].2003,3(4).
[38]Brown HS,Galetin A,Hallifax D,etc.Prediction of in vivo drug-drug interactions from in vitro data: factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4.[J].2006,45(10).
[39]Bogni A,Grossi P,Vignati LA,etc.A human and mouse pregnane X receptor reporter gene assay in combination with cytotoxicity measurements as a tool to evaluate species-specific CYP3A induction.[J].2004,199(1).
[40]Grimm SW,Einolf HJ,Hall SD.The conduct of in vitro studies to address time-dependent inhibition of drug-metabolizing enzymes: a perspective of the pharmaceutical research and manufacturers of America.[J].2009,37(7).
[41]Wang YH,Hall SD,Jones DR.Prediction of cytochrome p450 3a inhibition by verapamil enantiomers and their metabolites.[J].2004,32(2).
[42]Jamei M,Almond LM,Yang J.Towards a quantitative framework for the prediction of DDIs arising from cytochrome P450 induction.[J].2009,10(4).
[43]Miwa GT,Lu C,Balani SK,etc.A novel model for the prediction of drug-drug interactions in humans based on in vitro cytochrome p450 phenotypic data.[J].2007,35(1).
[44]Liras JL,Maurer TS,Trevena KA,etc.Use of immortalized human hepatocytes to predict the magnitude of clinical drug-drug interactions caused by CYP3A4 induction.[J].2006,34(10).